Drugs / KT-621
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06945458 | Apr → Nov 2025 | atopic eczema | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07677059 | Jul 2026 → Dec 2028 expected | asthma | Kymera Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07323654 | Jan 2026 → Dec 2027 expected | T2-high asthma | Kymera Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07217015 | Nov 2025 → Jun 2027 expected | atopic eczema | Kymera Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06673667 Comparator | Oct 2024 → Apr 2025 | — | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06673667 ↗ |
| Route | Oral | “Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-621.” NCT06673667 ↗ |